NTAGI group to review SII's Covovax data for use in 12 yrs and above

A Covid working group of NTAGI will review this week data of SII anti-coronavirus jab Covovax to decide whether it can be included vaccination programme for inoculating those aged 12 years and above

vaccine
Press Trust of India New Delhi
3 min read Last Updated : Mar 30 2022 | 4:37 PM IST

A Covid working group of NTAGI will review this week data of Serum Institute of India's (SII) anti-coronavirus jab Covovax to decide whether it can be included in the national COVID-19 vaccination programme for inoculating those aged 12 years and above, official sources said on Wednesday.

India's drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12 to 17 years age group subject to certain conditions on March 9.

Director (Government and Regulatory Affairs) at SII Prakash Kumar Singh recently had written to the health ministry urging it to include Covovax in the national COVID-19 vaccination drive for 12 years and above.

Singh stated that the Pune-based firm wants to provide Covovax to private hospitals at Rs 900 per dose plus GST and is also waiting for directions to supply the vaccine to the Centre but has not mentioned the price.

"The COVID-19 working group of the NTAGI is set to meet on April 1 and review the data of Covovax to decide whether it can be included in the national COVID-19 vaccination programme for inoculating those aged 12 years and above this week," an official source said.

In a letter to Health Secretary Rajesh Bhushan, Singh was learnt to have said that private companies, educational institutes, social organisations, central government organisations and public sector undertakings are making requests for Covovax to inoculate their staffers, families and children.

"Under the visionary leadership of our CEO Adar C Poonawalla, we have developed, manufactured and obtained emergency use authorisation from our national regulatory authority for one more world-class COVID-19 vaccine Covovax for 18 years and above on December 28, and for children in the age group of 12 to 17 years on March 9, 2022," an official source had quoted Singh as having said in the letter.

The country began inoculating children aged 12-14 from March 16.

The countrywide vaccination drive was rolled out on January 16 last year with healthcare workers getting inoculated in the first phase. Vaccination of frontline workers started from February 2 last year.

The next phase of COVID-19 vaccination commenced on March 1 last year for people over 60 years of age and those aged 45 and above with specified co-morbid conditions.

India launched vaccination for all people aged more than 45 years from April 1 last year. The government then decided to expand its vaccination drive by allowing everyone above 18 years of age to be inoculated against the viral disease from May 1 last year.

The next phase of vaccination commenced from January 3 for adolescents in the age group of 15-18 years.

India began administering precaution doses of vaccines to healthcare and frontline workers and those aged 60 and above with comorbidities from January 10.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineSerum Institute of India

First Published: Mar 30 2022 | 4:37 PM IST

Next Story